Keywords
Antiepileptic drugs
Lacosamide
Efficacy
Tolerability
How to Cite
Abstract
The focal seizures are one of the most widespread ones as they include various scopes of physical and psychological changes with a significant adverse impact on their well-being. Ever since anti-epileptic drugs (AEDs) are identified as a first-line treatment method, numerous patients encountered drug resistance and side effects. Lacosamide belongs to the third generation of anti-epileptic medication and is the best drug of the potential and preferred choice in treatment of focal seizures alone or as companion ecunicides. This narrative assessment examines the safety, effectiveness, tolerability, and clinical use of lacosamide in the treatment of epilepsy, drawing from 13 studies published from 2020 to 2024. All the studies revealed effectiveness of Lacosamide in reducing the frequency of the seizures with dose response and increase in the response rate over placebo. Additionally, it had an improved safety record and few adverse effects when compared to other antiepileptic drugs, particularly, among young individuals. The mode of action is selective in that; it amplifies the slow inactivation of sodium channels and causes minimal interference to the normal neural firing leading to fewer side effects and maximum control of seizures. Based on long-term studies, the efficacy of lacosamide is proven with continued seizure reduction and improved quality of life and cognitive status in both usage as monotherapy or adjuvant treatment. Even with all positive results, it has some challenges including clinicians' unfamiliarity with newer medications, expense-related factors and refusal to undergo treatment. To promote the clinical use of lacosamide on a large scale, eliminating these barriers by patient education, directing policy changes, and increasing access is vitally necessary. Altogether, lacosamide is a significant step towards treating focal epilepsy, and, given the effective safety balance, it could have a favorable influence on both patient outcomes and their livelihood.
References
Babar RK, Bresnahan R, Gillespie CS, Michael BD. Lacosamide add‐on therapy for focal epilepsy. Cochrane Database Syst Rev. 2021;2021(5):CD008841. doi: 10.1002/14651858.CD008841.pub3.
Mulheron S, Leahy TP, McStravick M, Doran R, Delanty N. Comparative efficacy and safety of lacosamide and oxcarbazepine for seizure control in children with newly diagnosed solitary neurocysticercosis. Seizure. 2024 Apr 5; 114:1–6. doi: 10.1016/j.seizure.2024.04.004
Özgün OT, Yılmaz MK, Atmaca MM, Güler SK, Buluş E, Duman A, Çelebi Ö, Gürses C. Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide. Epilepsy Behav. 2023 Aug; 145:109355. doi: 10.1016/j.yebeh.2023.109355.
Mohammadi T, Nasiri J, Ghazavi MR, Hosseini O. Efficacy of lacosamide add-on therapy on refractory focal epilepsies in children and adolescents: An open-label clinical trial. J Res Pharm Pract. 2022;11(1):17–22. doi: 10.4103/jrpp.jrpp_86_21.
Zaccara G, Giovannelli F, Maratea D, Specchio LM, Verrotti A. Lacosamide addon therapy for focal epilepsy. Cochrane Database Syst Rev. 2022;2022(5):CD008841. doi: 10.1002/14651858.CD008841.pub3.
Kumar A, Sharma S, Singh A, et al. Comparative efficacy and safety of lacosamide and oxcarbazepine for seizure control in children with newly diagnosed solitary neurocysticercosis. Seizure. 2024; 114:1–6. doi: 10.1016/j.seizure.2024.04.004.
Ebrahimpour S, Ghaffari S, Ghasemi M, et al. Efficacy of lacosamide add-on therapy on refractory focal epilepsies in children and adolescents. J Res Pharm Pract. 2022;11(1):17–22. doi: 10.4103/jrpp.jrpp_86_21.
Kellinghaus C, Trinka E, Ben-Menachem E, et al. Efficacy and tolerability of immediate switch from sodium channel blockers to lacosamide. Epilepsy Behav. 2023; 145:109355. doi: 10.1016/j.yebeh.2023.109355.
Trinka E, Ben-Menachem E, Kwan P, et al. Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial. Seizure. 2023; 110:1–7. doi: 10.1016/j.seizure.2023.09.011.
Villanueva V, Garcés M, López-González FJ, et al. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study. Epilepsy Behav. 2021; 121:108128. doi: 10.1016/j.yebeh.2021.108128.
Chung SS, Ben-Menachem E, Sperling MR, et al. Long-term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic-clonic seizures: An open-label extension trial. Epilepsia. 2023;64(6):1234–1243. doi:10.1111/epi.18158.
Wheless JW, Perry MS, Glauser TA, et al. Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy. Epilepsy Behav. 2024; 145:109989. doi: 10.1016/j.yebeh.2024.109989.
Alsaadi T, Benbadis SR, Kellinghaus C, et al. Serious adverse effects of selected antiseizure medications used for treatment of focal onset seizures. Expert Opin Drug Saf. 2024;23(4):345–356. doi:10.1080/14740338.2024.2446416.
Villanueva V, Mauri JA, Toledo M, et al. new evidence in adjunctive treatment of focal-onset seizures in adults: A critical appraisal. Glob Reg Health Technol Assess. 2022;9: GRHTA-2022-0020. doi:10.33393/grhta.2022.2420.
French JA, Kwan P, Brodie MJ. Epilepsy medication management: Addressing common treatment barriers to adopting cenobamate and other new antiseizure medications. Epilepsia. 2024. doi:10.1111/epi.18532.